Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT + TACE + Lenvatinib in advanced HCC with PVTT
NCT05592197Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 2 years. Planned start Oct 2018; status: withdrawn.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05592197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592197.